Sign Out
Ribomustin is indicated for monotherapy in patients with chronic lymphocytic leukaemia. Efficacy relative to first line therapies other than chlorambucil has not been established.
Ribomustin is indicated for monotherapy in patients with indolent B-cell non-Hodgkin's lymphomas that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
